Founded in August 2017, BiSiChem specializes in research on new drugs that mainly study anti-cancer drugs and develops targeted and immunosuppressive drugs and new drugs for Alzheimer’s dementia. It has researchers who have been developing new drugs and licensed out for nearly 20 to 30 years in the anti-cancer field such as medical centers and bio-research centers, and is focusing on developing targeted sub-molecular drugs for cancer (kinase inhibitors & immunosuppressants) and neuroscience (AD&PD) treatments. Seo Jeongbeob has been a senior researcher for several years at Array Biopharma in the United States and has served as CSO for Cha Biomed in Korea and CTO for CMG Pharmaceuticals.